Published in Hepatitis Weekly, September 20th, 2004
According to a report from Germany, "occurrence of thyroid autoimmunity and dysfunction following interferon-alpha treatment of viral hepatitis and other diseases are known adverse effects and have been ascribed to the cytokine's general immunomodulatory and activating properties. However, in spite of its extensive application, there have been few reports of such incidents during interferon-beta (IFN-beta-1a/b) therapy, which is considered the standard treatment of relapsing-remitting multiple sclerosis (MS), and prospective studies have been published only recently."
"Here we present the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.